|View printer-friendly version|
Dextera Surgical Provides Corporate Update
-- Preliminary Fiscal 2018 First Quarter Revenue --
-- Update on
-- Conference Call at
“As we have scaled up production of the MicroCutter 5/80, we have had
difficulty qualifying some of the raw material for our reloads and as a
result we experienced limited ability to ship product to our customers,”
Mr. Nikolchev continued, “While we continue to have active discussions with B. Braun regarding a strategic collaboration, these discussions are taking longer than expected and with support from our investment banker, the Board has decided to explore all strategic options available to us at this time.”
Conference Call Details
To access the live conference call today at
To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company’s website at ir.dexterasurgical.com. Please connect to the website at least 15 minutes prior to the presentation to allow for any necessary software downloads.
The webcast is also being distributed through the Thomson StreetEvents
Network. Institutional investors can access the call via
About Dextera Surgical
Dextera Surgical designs and manufactures proprietary stapling devices for minimally invasive surgical procedures. In the U.S., surgical staplers are routinely used in more than one million minimally invasive laparoscopic, video-assisted or robotic-assisted surgical procedures annually.
Dextera Surgical also markets the only automated anastomosis devices for coronary artery bypass graft (CABG) surgery on the market today: the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System. These products, sold by Dextera Surgical under the Cardica brand name, have demonstrated long-term reliable clinical performance for more than a decade.
The statements in this press release regarding the expected revenue for
the first quarter of fiscal 2018 are "forward-looking statements." There
are a number of important factors that could cause results to differ
materially from those indicated by these forward-looking statements,
including that the company has not closed its books for the quarter and
unexpected changes may be discovered during the closing process. Other